跳至主要内容
临床试验/CTRI/2024/01/061593
CTRI/2024/01/061593招募中4 期

Evaluation of efficacy and safety of low dose versus standard dose Emicizumab for the treatment of Hemophilia A – A randomized controlled trial - Nil

Department of Health Research, India0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All persons with haemophilia A(PWH)with FVIII levels less than 2 percentage as seen in case notes with age ranging from 2 to 17 years
  • PWH with and without the presence of FVIII inhibitors
  • PWH with inhibitors not planning for immune tolerance induction or where immune
  • tolerance induction has failed
  • PWH with hepatitis and HIV
  • Parents or patients willing to signed and give written informed consent or assent as
  • appropriate
  • Children and caregivers willing to comply with scheduled visits, treatment plans, laboratory
  • tests, and other study procedures, including the questionnaires.
  • Written or verbal assent as appropriate from children participating in the study

排除标准

  • Patients who will find it difficult to follow the protocol based on PI judgement
  • Patients posted for elective surgery
  • Inherited or acquired bleeding disorder other than hemophilia A
  • Ongoing Immune tolerance Induction therapy (prophylaxis regimens with FVIII and or
  • bypassing agents must be discontinued prior to enrollment)

研究者

发起方
Department of Health Research, India

相似试验

A clinical trial to study the efficacy and safety of... | 临床试验